Trevi Therapeutics, Inc.
NASDAQ:TRVIBiotechnology
+$0.43 today
- Market cap
- $1.93B
- Beta
- 1.05
- P/E (TTM)
- -53.6
- EPS (TTM)
- -$0.31
Volume 2.02M
Average 1.44M
TRVI Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Trevi Therapeutics, Inc.NASDAQ: TRVI
Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Financing cash flow declines year over year
Q3 FY2026 financing cash flow of $412K fell 74.7% year over year, behind the -4.0% change in trailing-twelve-month financing cash flow. Sequentially, it fell 99.7% from the prior quarter. Over 3 fiscal years it compounded at +2.8% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -74.7% toward the trailing-twelve-month pace of -4.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 121.01M USD
- Year-over-year change
- +96.8%
- 4-year CAGR
- +55.4%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 121.01M | +96.8% |
| FY2024 | 2024-12-31 | 61.48M | +877.3% |
| FY2023 | 2023-12-31 | (7.91M) | -107.1% |
| FY2022 | 2022-12-31 | 111.31M | +435.8% |
| FY2021 | 2021-12-31 | 20.78M | — |
Financing Cash Flow vs competitors
How TRVI compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -4.0% is the 5th highest of 9, against a peer median of +11.7%.
- Over three fiscal years its annual growth of +2.8% compares with a peer median of +32.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
VCREVicore Pharma Holding AB | LTM Jun 2026 | SEK 430.53M SEK | -48.4% | +32.0% | 32371.3% |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $271.31M USD | +71.7% | +89.7% | 1356.6% |
| LTM Sep 2026 | $165.28M USD | -4.0% | +2.8% | — | |
| LTM Jun 2026 | $51.05M USD | +154.8% | +82.6% | 4.5% | |
| LTM Mar 2026 | $45.45M USD | -60.7% | +65.1% | — | |
| LTM Jun 2026 | $40.85M USD | -75.7% | -2.8% | 9.1% | |
| LTM Mar 2026 | $40.83M USD | +2642.3% | — | 58.6% | |
| LTM Mar 2026 | $7.97M USD | +387.5% | -83.8% | 7.3% | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $3.07M USD | -99.2% | -37.4% | 92.5% |
| Peer median (excluding TRVI) | — | +11.7% | +32.0% | 58.6% | |
Competitors are the stored peer set for TRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (33.94M) | (29.15M) | (29.07M) | (47.91M) | (42.76M) |
| Depreciation & Amortization | 50K | 43K | 123K | 147K | 144K |
| Deferred Income Tax | (82K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.54M | 2.33M | 2.25M | 3.59M | 5.19M |
| Change in Working Capital | 1.51M | (1.23M) | (3.85M) | 6.83M | (3.49M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 831K | 9K | (1.05M) | 1.61M | (598K) |
| Other Working Capital | 678K | (1.24M) | (2.8M) | 5.22M | (2.89M) |
| Other Non-Cash Items | 974K | (162K) | (1.17M) | (907K) | (1.17M) |
| Operating Cash Flow | (28.95M) | (28.18M) | (31.71M) | (38.26M) | (42.09M) |
| Capital Expenditures | 0 | (159K) | (137K) | (35K) | (12K) |
| Acquisitions (Net) | 0 | (829K) | 0 | 0 | 0 |
| Purchases of Investments | 0 | (126.22M) | (9.93M) | (98.46M) | (170.66M) |
| Sales of Investments | 0 | 19M | 69.5M | 75.6M | 74.93M |
| Other Investing Activities | 0 | 829K | 0 | 1.37M | 1.64M |
| Investing Cash Flow | 0 | (107.37M) | 59.43M | (21.53M) | (94.11M) |
| Debt Repayment | (68K) | (5.83M) | (9.41M) | (126K) | 0 |
| Common Stock Issued | 21.18M | 105.41M | 1.71M | 61.15M | 120.3M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (340K) | 11.73M | (211K) | 464K | 714K |
| Financing Cash Flow | 20.78M | 111.31M | (7.91M) | 61.48M | 121.01M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (8.17M) | (24.24M) | 19.81M | 1.7M | (15.18M) |
| Free Cash Flow | (28.95M) | (28.33M) | (31.85M) | (38.29M) | (42.1M) |
Trevi Therapeutics, Inc.
NASDAQ:TRVI
Intrinsic Alpha fair value
Locked
Current Price
$13.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.